Phase III Open-Label Randomized Study of Eribulin Mesylate Versus Capecitabine in Patients With Locally Advanced or Metastatic Breast Cancer Previously Treated With an Anthracycline and a Taxane

Abstract

In this phase III study, eribulin was not shown to be superior to capecitabine with regard to OS or PFS.